Prioritising at-risk adults in vaccine coadministration trials

Harboe, Zitta Barrella; Rezahosseini, Omid; Eberhardt, Christiane Sigrid

doi:10.1016/S1473-3099(24)00674-1

Scientific article

Comment

English

Prioritising at-risk adults in vaccine coadministration trials

ContributorsHarboe, Zitta Barrella; Rezahosseini, Omid; Eberhardt, Christiane Sigrid

Published inLancet. Infectious diseases, vol. 25, no. 4, p. 362-363

Publication date2025-04

First online date2024-11-25

Abstract

Refers to : Goswami J, Cardona JF, Hsu DC, Simorellis AK, Wilson L, Dhar R, Tomassini JE, Wang X, Kapoor A, Collins A, Righi V, Lan L, Du J, Zhou H, Stoszek SK, Shaw CA, Reuter C, Wilson E, Miller JM, Das R; study investigators. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. Lancet Infect Dis. 2025 Apr;25(4):411-423. doi: 10.1016/S1473-3099(24)00589-9. Epub 2024 Nov 25. PMID: 39608389.

Affiliation entities

Research groups

Immunologie adaptative - centre de vaccinologie (1061)

Citation (ISO format)

HARBOE, Zitta Barrella, REZAHOSSEINI, Omid, EBERHARDT, Christiane Sigrid. Prioritising at-risk adults in vaccine coadministration trials. In: Lancet. Infectious diseases, 2025, vol. 25, n° 4, p. 362–363. doi: 10.1016/S1473-3099(24)00674-1

Article (Published version)

Identifiers

PID : unige:189164
DOI : 10.1016/S1473-3099(24)00674-1
PMID : 39608387

Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S1473309924006741

Journal ISSN1473-3099

29views

0downloads

Creation14/10/2025 07:53:04

First validation26/11/2025 08:16:58

Update24/03/2026 08:44:36

Status update24/03/2026 08:44:36

Last indexation24/03/2026 08:46:16

Archive ouverte UNIGE

Prioritising at-risk adults in vaccine coadministration trials

Technical informations